JOHNSON CONTROLS INTERNATIONAL PLC (JCI)
Sector: Industrials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Industrials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for JCI
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| JCI | Retired Chief Business Officer, Pfizer Inc.; Director; Chair | 61 | ["Extensive experience as a business leader with 30 years of experience with Pfizer.", "Specialized expertise in developing healthcare solutions in a variety of medical disciplines, utilizing technology and innovation.", "Experience in corporate social responsibility as a member of the Board of the Pfizer Foundation and his role in overseeing Pfizer\u2019s sustainability strategy and commitments.", "Experience leading large business units at Pfizer.", "Significant experience in a number of senior global positions at Pfizer.", "Served as the Chief Business Officer of Pfizer Inc. from January 2019 until December 2021 and Special Advisor to the CEO from January 2022 until his retirement in July 2022.", "Served as Group President of Pfizer Innovative Health from January 2018 to December 2018", "Served as Group President, Pfizer Essential Health from June 2016 to January 2018.", "Held various other roles at Pfizer, including Group President, Global Established Pharma Business from January 2014 until June 2016 and President and General Manager, Pfizer Primary Care from June 2012 until December 2013.", "Served as Pfizer\u2019s Primary Care Business Unit\u2019s Regional President for Europe and Canada from 2009 until June 2012 and U.K. Country Manager from 2007 until 2009.", "Currently a director of Novartis AG, a multinational company specializing in the research, development, manufacturing and marketing of innovative pharmaceuticals and generic medicines.", "Previously a director of Arvinas, Inc., a clinical-stage biopharmaceutical company."] | ["CC", "Compensation"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PFE | FORMER GROUP PRESIDENT, CHIEF BUSINESS OFFICER | ["Led the Portfolio Strategy and Investment Committee","Optimized capital allocations across the R&D portfolio","Executed business development transactions","Accelerated mRNA platform development","Implemented transformative system changes","Executed innovative contracts aligning incentives","Validated blockchain technology with payer collaborations"] | ["Portfolio Strategy and Investment Committee"] | 2022 |
Biography sourced from the proxy statement filing.
Served as the Chief Business Officer of